A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
ConditionMultiple Myeloma
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorJanssen Research & Development, LLC
About this trial
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria
Measurable disease at screening as assessed by central laboratory
Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD) 38 monoclonal antibody (mAb)
Documented evidence of progressive disease(PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by the IMWG criteria
Disqualifiers
None
Trial design
Design model
Single group
Treatments tested in this trial
JNJ-79635322
DrugJNJ-79635322 will be administered as an injection under the skin.
Treatment groups
157 Participants
are divided into 1 treatment groupGroup A: JNJ-79635322Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Overall Response Rate (ORR)
Time frame
Up to 2 years and 9 monthsSecondary outcomes
1
Very Good Partial Response (VGPR) or Better Rate
Time frame
Up to 2 years and 9 months2
Complete Response (CR) or Better Rate
Time frame
Up to 2 years and 9 months3
Duration of Response (DoR)
Time frame
Up to 2 years and 9 months4
Progression-Free Survival (PFS)
Time frame
Up to 2 years and 9 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov